The presence of tertiary lymphoid structures (TLSs)—ectopic lymphoid tissues that develop within tumors—has recently emerged as a critical biomarker for predicting favorable responses to cancer immunotherapy. However, finding effective therapeutic strategies to actively induce the formation of these organized structures has remained a significant clinical hurdle. While Interleukin-7 (IL-7) is a vital cytokine known to support T cell survival and lymphoid organogenesis, its short half-life severely limits its therapeutic application.

This new research, published in the Genes & Diseases journal by a team from Case Western Reserve University, Northwestern University, and Emory University, investigated the therapeutic efficacy of efineptakin alfa (NT-I7), a long-acting recombinant human IL-7 fusion protein, to comprehensively remodel the tumor immune microenvironment.

Through rigorous in vivo evaluations using murine lung (LLC1) and colorectal (CT26) tumor models, the researchers discovered that NT-I7 administration improves overall survival in tumor-bearing mice. Flow cytometry and extensive immunofluorescence analyses revealed that NT-I7 treatment significantly increases the abundance of vital tumor-infiltrating immune cells, specifically T cells, B cells, and conventional dendritic cells. Crucially, the systemic treatment promoted the formation of large, organized immune aggregates within the tumor microenvironment. These newly formed TLS-like structures contained highly functional zones deeply enriched with the lymphoid neogenesis cytokine lymphotoxin beta (Ltb) and essential antigen-processing genes like Cd74 and B2m.

A significant discovery within this immune remodeling was the dynamic shift in the T cell landscape. The researchers noted a significant expansion of stem-like CD8 T cells (TCF-1+ TIM-3-), and strikingly demonstrated that over 73% to 79% of these crucial stem-like CD8 T cells were preferentially localized directly within or adjacent to the NT-I7-induced immune aggregates.

To fully map the functional environment of these immune aggregates, the team utilized advanced spatial transcriptomics. This high-resolution mapping unraveled an intriguing dual-nature within the TLS-like structures: alongside heightened immune activation, there was a significant localized enrichment of the coinhibitory transcript Cd274 (PD-L1). Rather than a setback, this specific upregulation of the PD-L1 pathway within the densely populated TLS niches exposes a distinct therapeutic vulnerability. Because the clinical efficacy of PD-1 checkpoint blockade heavily relies on the proliferative burst of stem-like CD8 T cells, the NT-I7-driven accumulation of these specific cells inside PD-L1-rich structures creates an ideal environment for combinatorial synergy.

In conclusion, utilizing long-acting NT-I7 offers a powerful new strategy to actively engineer immune-permissive TLS niches within hostile solid tumors. This significant finding positions NT-I7 as a highly compelling therapeutic candidate, uniquely primed to be paired with PD-1 immune checkpoint inhibitors to deliver deeper and more durable clinical remissions for cancer patients.

Reference
Title of Original Paper: Efineptakin alfa (NT-I7) improves overall survival and induces immune niches murine tumors

Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI: https://doi.org/10.1016/j.gendis.2026.102136

Funding Information:
The American Lung Association Catalyst Award (CA- 826809)

# # # # # #

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus Cite Score: 10.4 | Impact Factor: 14.6

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #